GTC Biotherapeutics (fka GTCB)

[n4807g]

What you suggest about the lack of interest has merit and may be true in general. However, I am assuming that the political pressure to make health care (in general) less costly as the need (read population ages) grows will force congress to act on F.O.B. sooner, rather then later.

I am also assuming that the technology platform is more efficient and cost effective when applied to specific compounds (MM-093, Protexia). If F.O.B. legislation wasn't a possibility and the need for lower cost drugs wasn't an issue then GTC would have a difficult time convincing investors that the company had a competitive advantage to exploit. I'm also assuming that GTC is/has been talking to several companies. We may all be surprised in the end. But I don't discount the possibility that they have or are talking to BP.

It will be interesting to see how the news unfolds in the coming weeks.